药物性肝损伤发生机制、危险因素、监测以及再用药的研究进展

刘茹佳; 辛小娟

doi:10.3969/j.issn.1001-5256.2023.04.034

药物性肝损伤发生机制、危险因素、监测以及再用药的研究进展

DOI: 10.3969/j.issn.1001-5256.2023.04.034

刘茹佳,
辛小娟^, ,

重庆医科大学附属第一医院感染科，重庆 400016

基金项目:

重庆市科卫联合医学科研项目 (2019ZDXM004)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：刘茹佳负责收集、分析资料，撰写文章；辛小娟负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
辛小娟，1152592844@qq.com (ORCID: 0000-0002-5463-9702)

计量
- 文章访问数: 413
- HTML全文浏览量: 96
- PDF下载量: 109
- 被引次数: 0
出版历程
- 收稿日期: 2022-08-14
- 录用日期: 2022-09-26
- 出版日期: 2023-04-20

Research advances in pathogenesis, risk factors, monitoring, and retreatment of drug-induced liver injury

Rujia LIU,
Xiaojuan XIN^{,
,}

Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Research funding:

Chongqing Science and Health Joint Medical Research Project (2019ZDXM004)

More Information

Corresponding author: XIN Xiaojuan, 1152592844@qq.com (ORCID: 0000-0002-5463-9702)

摘要

摘要: 随着大量新药的审批上市，药物性肝损伤(DILI)发病率逐年升高，并可能影响患者原发病治疗。DILI作为药物不良反应不可能被完全消灭，临床目标是通过预防和控制将其影响降至最低。本文综述了DILI的危险因素和DILI监测以及再用药的相关研究进展。研究表明，某些因素在特定条件下可增加DILI的发生风险。通过早期识别DILI的危险因素，合理监测，注意再用药的时机和方法，能够减少DILI的发生或进展，改善患者预后。
- 化学性与药物性肝损伤 /
- 危险因素 /
- 再治疗
Abstract: With the approval and launch of a large number of new drugs, the incidence rate of drug-induced liver injury (DILI) is increasing year by year, which may affect the treatment of primary diseases. As an adverse drug reaction, DILI cannot be completely eliminated, and the clinical goal is to minimize its influence through prevention and control. This article reviews the research advances in the risk factors for DILI, the monitoring of DILI, and retreatment. Studies have shown that the risk of DILI can be increased by certain factors under some circumstances. Early identification of risk factors, rational monitoring, and focus on the timing and method for retreatment can reduce the development or progression of DILI and thus improve the prognosis of patients.
- Chemical and Drug Induced Liver Injury /
- Risk Factors /
- Retreatment

HTML全文

参考文献(35)

[1]	CHURCH RJ, KULLAK-UBLICK GA, AUBRECHT J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort[J]. Hepatology, 2019, 69(2): 760-773. DOI: 10.1002/hep.29802.
[2]	AITHAL GP, WATKINS PB, ANDRADE RJ, et al. Case definition and phenotype standardization in drug-induced liver injury[J]. Clin Pharmacol Ther, 2011, 89(6): 806-815. DOI: 10.1038/clpt.2011.58.
[3]	SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. DOI: 10.1053/j.gastro.2019.02.002.
[4]	DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines[J]. Hepatol Int, 2021, 15(2): 258-282. DOI: 10.1007/s12072-021-10144-3.
[5]	WANG Q, HUANG A, WANG JB, et al. Chronic drug-induced liver injury: updates and future challenges[J]. Front Pharmacol, 2021, 12: 627133. DOI: 10.3389/fphar.2021.627133.
[6]	CHALASANI NP, MADDUR H, RUSSO MW, et al. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898. DOI: 10.14309/ajg.0000000000001259.
[7]	LUCENA MI, SANABRIA J, GARCÍA-CORTES M, et al. Drug-induced liver injury in older people[J]. Lancet Gastroenterol Hepatol, 2020, 5(9): 862-874. DOI: 10.1016/S2468-1253(20)30006-6.
[8]	JEE A, SERNOSKIE SC, UETRECHT J. Idiosyncratic drug-induced liver injury: Mechanistic and clinical challenges[J]. Int J Mol Sci, 2021, 22(6): 2954. DOI: 10.3390/ijms22062954.
[9]	LI X, TANG J, MAO Y. Incidence and risk factors of drug-induced liver injury[J]. Liver Int, 2022, 42(9): 1999-2014. DOI: 10.1111/liv.15262.
[10]	KANTARJIAN H, THOMAS D, JORGENSEN J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia[J]. Cancer, 2013, 119(15): 2728-2736. DOI: 10.1002/cncr.28136.
[11]	GARCÍA-ROMÁN R, FRANCÉS R. Acetaminophen-induced liver damage in hepatic steatosis[J]. Clin Pharmacol Ther, 2020, 107(5): 1068-1081. DOI: 10.1002/cpt.1701.
[12]	SONG XA, ZHANG X, WEI ZM, et. al. The characteristics and rules of liver injury induced by antifungal drugs in elderly population[J]. World Clin Drugs, 2019, 40(12): 891-895. DOI: 10.13683/j.wph.2019.12.014. 宋雪艾, 张昕, 魏智民, 等. 老年人群应用抗真菌药致肝损伤的特点及规律分析[J]. 世界临床药物, 2019, 40(12): 891-895. DOI: 10.13683/j.wph.2019.12.014.
[13]	SUN Q, ZHANG Q, GU J, et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study[J]. Pharmacoepidemiol Drug Saf, 2016, 25(8): 908-917. DOI: 10.1002/pds.3988.
[14]	ALONSO A, MACLEHOSE RF, CHEN LY, et al. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation[J]. Heart, 2017, 103(11): 834-839. DOI: 10.1136/heartjnl-2016-310586.
[15]	LOUVET A, NTANDJA WANDJI LC, LEMAÎTRE E, et al. Acute liver injury with therapeutic doses of acetaminophen: A prospective study[J]. Hepatology, 2021, 73(5): 1945-1955. DOI: 10.1002/hep.31678.
[16]	PUKENYTE E, LESCURE FX, REY D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment[J]. Int J Tuberc Lung Dis, 2007, 11(1): 78-84.
[17]	PARK JH, HONG S, JUN DW, et al. Prevalence and clinical characteristics of antibiotics associated drug induced liver injury[J]. Ann Transl Med, 2021, 9(8): 642. DOI: 10.21037/atm-20-5144.
[18]	KONG X, GUO D, LIU S, et al. Incidence, characteristics and risk factors for drug-induced liver injury in hospitalized patients: A matched case-control study[J]. Br J Clin Pharmacol, 2021, 87(11): 4304-4312. DOI: 10.1111/bcp.14847.
[19]	SHAO Q, MAO X, ZHOU Z, et al. Research progress of pharmacogenomics in drug-induced liver injury[J]. Front Pharmacol, 2021, 12: 735260. DOI: 10.3389/fphar.2021.735260.
[20]	NICOLETTI P, AITHAL GP, BJORNSSON ES, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study[J]. Gastroenterology, 2017, 152(5): 1078-1089. DOI: 10.1053/j.gastro.2016.12.016.
[21]	LI C, RAO T, CHEN X, et al. HLA-B^*35: 01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70(1): 346-357. DOI: 10.1002/hep.30660.
[22]	SU Q, LIU Q, LIU J, et al. Study on the associations between liver damage and antituberculosis drug rifampicin and relative metabolic enzyme gene polymorphisms[J]. Bioengineered, 2021, 12(2): 11700-11708. DOI: 10.1080/21655979.2021.2003930.
[23]	WATANABE I, TOMITA A, SHIMIZU M, et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus[J]. Clin Pharmacol Ther, 2003, 73(5): 435-455. DOI: 10.1016/s0009-9236(03)00014-6.
[24]	MAO L, LIN P, ZHANG W, et al. Case analysis of medical disputes related to drug-induced liver injury in Beijing from 2013 to 2019[J]. ADRJ, 2021, 23(11): 564-569. DOI: 10.3760/cma.j.cn114015-20210412-00442. 毛璐, 林平, 张威, 等. 北京市2013—2019年药物性肝损伤相关医疗纠纷案例分析[J]. 药物不良反应杂志, 2021, 23(11): 564-569. DOI: 10.3760/cma.j.cn114015-20210412-00442.
[25]	Chinese Society of Tuberculosis, Chinese Medical Association. Guidelines for the management of antituberculous drug-induced liver injury (2019 edition)[J]. Chin J Tuberc Respir Dis, 2019, 42(5): 343-356. DOI: 10.3760/cma.j.issn.1001-0939.2019.05.007. 中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版)[J]. 中华结核和呼吸杂志, 2019, 42(5): 343-356. DOI: 10.3760/cma.j.issn.1001-0939.2019.05.007.
[26]	MOED S, SUPRENANT M, ODJIDJA EN, et al. Economic evaluation of screening interventions for drug-induced liver injury[J]. Clin Infect Dis, 2021, 73(11): e3959-e3965. DOI: 10.1093/cid/ciaa1347.
[27]	MCGILL MR, STAGGS VS, SHARPE MR, et al. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome[J]. Hepatology, 2014, 60(4): 1336-1345. DOI: 10.1002/hep.27265.
[28]	DEAR JW, CLARKE JI, FRANCIS B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies[J]. Lancet Gastroenterol Hepatol, 2018, 3(2): 104-113. DOI: 10.1016/S2468-1253(17)30266-2.
[29]	HUNT CM, PAPAY JI, STANULOVIC V, et al. Drug rechallenge following drug-induced liver injury[J]. Hepatology, 2017, 66(2): 646-654. DOI: 10.1002/hep.29152.
[30]	ANDRADE RJ, ROBLES M, LUCENA MI. Rechallenge in drug-induced liver injury: the attractive hazard[J]. Expert Opin Drug Saf, 2009, 8(6): 709-714. DOI: 10.1517/14740330903397378.
[31]	DOUGAN M, WANG Y, RUBIO-TAPIA A, et al. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: Expert review[J]. Gastroenterology, 2021, 160(4): 1384-1393. DOI: 10.1053/j.gastro.2020.08.063.
[32]	HENRIKSEN JN, B∅TTGER P, HERMANSEN CK, et al. Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: Effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes[J]. Clin Genitourin Cancer, 2020, 18(1): 62-68. DOI: 10.1016/j.clgc.2019.09.013.
[33]	OH JH, YUN J, YANG MS, et al. Reintroduction of antituberculous drugs in patients with antituberculous drug-related drug reaction with eosinophilia and systemic symptoms[J]. J Allergy Clin Immunol Pract, 2021, 9(9): 3442-3449. DOI: 10.1016/j.jaip.2021.03.054.
[34]	MINERALI E, FOIL DH, ZORN KM, et al. Comparing machine learning algorithms for predicting drug-induced liver injury (DILI)[J]. Mol Pharm, 2020, 17(7): 2628-2637. DOI: 10.1021/acs.molpharmaceut.0c00326.
[35]	WATKINS PB. Quantitative systems toxicology approaches to understand and predict drug-induced liver injury[J]. Clin Liver Dis, 2020, 24(1): 49-60. DOI: 10.1016/j.cld.2019.09.003.